Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities.
Garvey
D S
DS
Neuroscience Research Division, Abbott Laboratories, Abbott Park, Illinois 60064.
Wasicak
J T
JT
Decker
M W
MW
Brioni
J D
JD
Buckley
M J
MJ
Sullivan
J P
JP
Carrera
G M
GM
Holladay
M W
MW
Arneric
S P
SP
Williams
M
M
D000470:Alkaloids / Q000378:metabolism; D000818:Animals; D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000494:pharmacology*; D001392:Azocines; D001665:Binding Sites; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D002038:Bungarotoxins / Q000378:metabolism; D003071:Cognition / Q000187:drug effects*; D007555:Isoxazoles / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D051379:Mice; D015394:Molecular Structure; D009043:Motor Activity / Q000187:drug effects; D009538:Nicotine / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D011807:Quinolizines; D051381:Rats; D011950:Receptors, Cholinergic / Q000378:metabolism*; D011978:Receptors, Nicotinic / Q000378:metabolism; D013237:Stereoisomerism; D000093843:Quinolizidine Alkaloids
D000470:Alkaloids; D014151:Anti-Anxiety Agents; D001392:Azocines; D002038:Bungarotoxins; D007555:Isoxazoles; D009538:Nicotine; D011807:Quinolizines; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; C004712:cytisine; D000093843:Quinolizidine Alkaloids; C005311:nornicotine